Eyenovia Reports Q1 Loss and Pursues Merger with Betaliq

Introduction

Eyenovia Inc. (NASDAQ: EYEN) is an ophthalmic technology company that develops and commercializes drug-device combinations aimed at treating front-of-eye diseases. The company’s proprietary Optejet® platform delivers topical ophthalmic medications in a metered dose, which is intended to enhance ease of use, safety, and patient compliance compared to traditional eye drops.

Corporate Structure

Founded in 2014 and headquartered in New York, New York, Eyenovia operates as a publicly traded entity on NASDAQ under the ticker EYEN. The company employs between 51 and 200 people in roles that include research and development, regulatory affairs, manufacturing, and commercial functions. The leadership team is headed by Chief Executive Officer Michael Rowe.

Developments and News

On May 19, 2025, Eyenovia reported its financial results for the first quarter of 2025 and provided updates on two strategic initiatives:

• Potential Merger with Betaliq: Eyenovia is negotiating a binding merger agreement with Betaliq, a clinical-stage pharmaceutical company focused on glaucoma utilizing its Eyesol® water-free delivery technology. This negotiation is being conducted under a non-binding Letter of Intent, with the exclusivity period extended through June 7, 2025.
• Optejet User-Filled Device (UFD): Development of the Optejet UFD is on track for a U.S. regulatory filing in September 2025.

In the first quarter of 2025, a broad restructuring was implemented, resulting in a reduction of cash burn by approximately 70% year-over-year, along with entering into debt restructuring agreements that defer specific repayment obligations until October 2025. As of March 31, 2025, Eyenovia reported $3.9 million in unrestricted cash and cash equivalents.

On June 13, 2025, a Schedule 13D/A filing disclosed that Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. collectively hold about 9.99% of Eyenovia’s common stock. This includes the potential conversion of outstanding loans totaling approximately $9.73 million into more than 5.5 million shares at a conversion price of $1.68 per share, which could result in significant dilution if executed.

Eyenovia’s LinkedIn page highlights a non-binding Letter of Intent for a reverse merger with Betaliq. If successful, the combined public company would market Eyenovia’s FDA-approved products and may in-license additional candidates to generate immediate revenue.

Financial and Strategic Analysis

At market close on June 16, 2025, EYEN shares were priced at $4.20, reflecting a 41.41% increase on a volume of 1,018,941 shares. Key metrics from Yahoo Finance include:

• Previous close: $2.44
• 52-week range: $0.85 – $124.80
• Market capitalization (intraday): $7.84 million
• Enterprise value: $14.25 million
• Price/Sales (TTM): 44.92
• Return on Assets (TTM): –117.74%
• Trailing diluted EPS (TTM): –42.65
• Total cash (MRQ): $3.93 million
• Revenue (TTM): $67,060

For the first quarter of 2025, the net loss was $3.5 million, or $1.59 per share, compared to a net loss of $10.9 million, or $18.75 per share, in the first quarter of 2024. Research and development expenses decreased by 85% to $0.7 million, while general and administrative expenses fell by 35% to $2.4 million. Total operating expenses for Q1 2025 were reduced by 70% to $3.0 million.

Strategically, Eyenovia aims to balance near-term liquidity needs—supported by convertible debt and expense reductions—with longer-term growth through potential merger synergies and the imminent UFD regulatory submission. The structure of the convertible loans provides financial flexibility, although it poses a risk of equity dilution if conversion rights are exercised.

Market Position and Industry Context

Eyenovia operates within the ophthalmology segment of pharmaceutical manufacturing, focusing on chronic front-of-eye conditions such as postoperative inflammation, presbyopia, and glaucoma. Its Optejet platform distinguishes itself through the ability to deliver precise micro-doses via a reusable device, aiming to overcome limitations of standard eye drops, including mis-dosing and waste. Notable collaborations include Arctic Vision for commercialization in China and Korea. A successful merger with Betaliq would enhance Eyenovia’s pipeline with Eyesol’s water-free glaucoma formulation, potentially expanding its breadth in the eye-care market.

tl;dr

On May 19, 2025, Eyenovia reported a Q1 2025 net loss of $3.5 million—down 68% year-over-year—and has deferred debt repayments until October 2025. The company is engaging in merger negotiations with Betaliq under an exclusivity extension through June 7, 2025, and is on schedule to file for U.S. regulatory approval of its Optejet UFD in September 2025. As of June 13, 2025, Avenue Capital funds hold 9.99% of shares, with convertible loans that could result in the issuance of up to 5.5 million additional shares. Investors will track the merger outcome, the September device submission, and any potential conversion decisions that may lead to dilution.